Caplacizumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), G-BA (Germany) and NICE (England), among others, recommended or restricted caplacizumab, while CIPM (Spain), DMC (Denmark) and PBAC (Australia) did not recommend it.
Assessment has run over 5.3 years, from 5 Mar 2019 at AWMSG (Wales) to 24 Jul 2024 at AOTMIT (Poland).
AOTMIT (Poland) changed its position: not recommended on 30 Sep 2021, recommended by 24 Jul 2024, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Against its own class, caplacizumab is an outlier: 57% of its decisive outcomes were positive, where molecules sharing ATC class B01A average 80%.
5 distinct indication wordings are recorded for caplacizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 16 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess caplacizumab, on 5 Mar 2019; AOTMIT (Poland) did not open a file until 30 Sep 2021 — a moderate spread of 2.5 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 7 of 16 dated records fall in 2020 alone.
Restriction is doing real work here: 4 of 14 decisive outcomes narrowed caplacizumab to a subgroup rather than accepting or refusing it outright, at AIFA (Italy), G-BA (Germany) and NICE (England).
5 of the 10 agencies here assessed caplacizumab more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for caplacizumab.
The full ledger for caplacizumab reads 6 not recommended, 4 recommended, 4 restricted and 1 deferred to NICE, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 24 Jul 2024 | Cablivi reimbursement recommendation | recommended | source |
| HAS (France) | 6 Oct 2021 | Re-assessment of SMR and ASMR | SMR insufficient · ASMR IV | source |
| G-BA (Germany) | 7 Jan 2021 | Cablivi — benefit assessment §35a | added benefit: non-quantifiable (hint) | source |
| CIPM (Spain) | 17 Dec 2020 | Indicación terapéutica: Cablivi está indicado para el tratamiento de adulto s y adolescentes a partir de 12 años que pes… | not financed by the SNS · art. 92 d | source |
| NICE (England) | 16 Dec 2020 | NICE TA667 | recommended (optimised) | source |
11 further decisions for caplacizumab, across 8 agencies, are not shown here. They link to 8 further source documents.
Related molecules
- rivaroxaban — same ATC class B01A — Antithrombotics
- apixaban — same ATC class B01A — Antithrombotics
- enoxaparin — same ATC class B01A — Antithrombotics
- dabigatran — same ATC class B01A — Antithrombotics
- fondaparinux — same ATC class B01A — Antithrombotics
- ticagrelor — same ATC class B01A — Antithrombotics
Coverage: 16 decisions for caplacizumab from 10 agencies, 2019 to 2024. Data to 7 Sep 2026. ATC class B01A — Antithrombotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.